Murakami S, et al. - Researchers conducted this phase II study to assess the tolerability and efficacy of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer. They recognized nedaplatin and irinotecan as a tolerable regimen for adjuvant chemotherapy. In addition, the regimen was associated with adequate 5-year disease-free survival and overall survival rates.